Spotlight commentary: Navigating between financial risks and improved treatment outcomes with immune checkpoint inhibitors in cancer patients: The need for biomarker identification and dose optimization.

Likic, Robert; Dear, James W; Lewis, Lionel D

Likic, Robert; Dear, James W; Lewis, Lionel D.

Afiliación

Likic R; University of Zagreb Medical School, Zagreb, Croatia.
Dear JW; Department of Internal Medicine, Division of Clinical Pharmacology and Therapeutics, Clinical Hospital Centre Zagreb, Zagreb, Croatia.
Lewis LD; Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.

Br J Clin Pharmacol ; 88(12): 5060-5063, 2022 12.

Article en En | MEDLINE | ID: mdl-36206769

Asunto(s)

Inhibidores de Puntos de Control Inmunológico; Neoplasias; Humanos; Inhibidores de Puntos de Control Inmunológico/efectos adversos; Neoplasias/tratamiento farmacológico; Ipilimumab; Resultado del Tratamiento; Biomarcadores; Protocolos de Quimioterapia Combinada Antineoplásica

Palabras clave

checkpoint inhibitors; dose optimization; ipilimumab; nivolumab; pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Diagnostic_studies / Etiology_studies / Health_economic_evaluation / Risk_factors_studies Límite: Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Croacia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google